MRNS Stock Overview
A pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Marinus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.73 |
| 52 Week High | US$11.26 |
| 52 Week Low | US$1.05 |
| Beta | 1.12 |
| 11 Month Change | 17.69% |
| 3 Month Change | 47.86% |
| 1 Year Change | -79.00% |
| 33 Year Change | -84.80% |
| 5 Year Change | -69.11% |
| Change since IPO | -94.59% |
Recent News & Updates
A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price
Sep 20
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 16Recent updates
A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price
Sep 20Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target
May 11Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%
Apr 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 08Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Dec 22Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?
Sep 22Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S
Jun 12Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically
May 16Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts
Oct 26Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?
Oct 12Marinus Pharmaceuticals: Positive News Flow Of Note
Sep 22Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M
Aug 29Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher
Aug 13Marinus Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy
Jul 28Revisiting Marinus Pharmaceuticals
May 05Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues
Mar 27Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Mar 03Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption
Feb 28Shareholder Returns
| MRNS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 8.1% | -1.4% | 0.6% |
| 1Y | -79.0% | 22.2% | 32.1% |
Return vs Industry: MRNS underperformed the US Pharmaceuticals industry which returned 22.3% over the past year.
Return vs Market: MRNS underperformed the US Market which returned 31.9% over the past year.
Price Volatility
| MRNS volatility | |
|---|---|
| MRNS Average Weekly Movement | 11.5% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MRNS's share price has been volatile over the past 3 months.
Volatility Over Time: MRNS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 166 | Scott Braunstein | marinuspharma.com |
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.
Marinus Pharmaceuticals, Inc. Fundamentals Summary
| MRNS fundamental statistics | |
|---|---|
| Market cap | US$95.85m |
| Earnings (TTM) | -US$149.24m |
| Revenue (TTM) | US$30.26m |
3.1x
P/S Ratio-0.6x
P/E RatioIs MRNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRNS income statement (TTM) | |
|---|---|
| Revenue | US$30.26m |
| Cost of Revenue | US$97.43m |
| Gross Profit | -US$67.16m |
| Other Expenses | US$82.08m |
| Earnings | -US$149.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.71 |
| Gross Margin | -221.93% |
| Net Profit Margin | -493.14% |
| Debt/Equity Ratio | -200.5% |
How did MRNS perform over the long term?
See historical performance and comparison